Sanofi Vaccine Sales Jump 50 Percent In Q3
This article was originally published in The Pink Sheet Daily
Executive Summary
Performance of vaccines business helps offset slight decline in pharmaceuticals revenues, hard hit by Ambien IR generics.
You may also be interested in...
Sanofi’s Menactra Use Expanded To Children
Sanofi Pasteur’s meningococcal conjugate vaccine approved for use in children 2 years to 10 years old.
Court Rules Against Sanofi In Lovenox Patent Case Again; Second Round Of Appeals Likely
Denial of a second appeal of a U.S. District Court’s decision that Teva and Amphastar are not infringing the Lovenox patent could open door to generic launches.
Menactra Supply Shortage Will Be Resolved By Fall, FDA Says
CDC recommends Sanofi Pasteur’s oral meningococcal disease vaccine Menomune as an “acceptable alternative” to the firm’s intramuscular vaccine.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: